Patrick Johnson, Lilly International President, on India's investment appeal.
India is well-positioned to attract future investments due to its improving regulatory environment, according to Patrick Johnson, President of Lilly International. Johnson highlighted the importance of faster, predictable, and globally aligned clinical trial approvals in making India a more attractive destination for high-value research and development.
In a statement, Johnson, also Executive Vice President of Eli Lilly and Company, emphasized that streamlined clinical trial processes are critical for India to strengthen its scientific capability and capacity. This focus on regulatory efficiency is expected to encourage more pharmaceutical companies to invest in research and manufacturing within India.
The comments come as India aims to boost its pharmaceutical sector and become a global hub for drug discovery and manufacturing. Policy reforms and improvements in the ease of doing business are seen as vital steps in achieving this goal. The government’s efforts to align clinical trial approvals with global standards are expected to enhance India’s competitiveness in attracting foreign investment in the pharmaceutical industry.
About the Author
